<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 297 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page296.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=297">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 297 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 297</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=297"><img src="../thumb/297.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>260 / 2020-04                                                        Anti-Microbials - 18.11 / 18.12
   Indications: Ac.treatm.of mild.to mod. pneumocystis carinii pneu-  to 200 mg 8-12 hrly may prove effect. Interrupt at 6-12 mnthly. interv.   dipivoxil/ dofetilide/ pilsicainide/didanosine/metformin, pts. &lt; 18 yrs.,
   mon.(PCP) when intol.to co-trimoxazole.  to observe any poss.changes.  mod.to sev.liv funct.impairm.
   (S4) SUSP, 31/20.2.6/0033. 750 mg/5 ml.  H.simplex prophylax in immunocomprom. adults: 200 mg   Side effects: Freq: Hyperlactataem., headache, insomn, N&V, up-
   864587-008: 210 ml, R3 885,45  4xdly 6 hrly. In sev.compromis. pts. /pts. with imp.gut absorpt.dos.  per abdom. pain, diarrh., rash, alopec., prurit., arthralg., musc.disord.,
   Dosage: Full prescrib.dos.must be taken with food. 5 ml 2 xdly   may be doubl.to 400 mg.or IV ther consid., durat.of ther.determin.   fatig., malaise, fev., dizzin., flatul., abnorm.dreams. Less freq: Neu-
   x 21 days. Where diffic.in swallow. exper.admin.10 ml once dly.x   by period at risk.  tropen., anaem., thrombocytopen., pure red cell aplas., lact. acidos./
   21 days                      H.zoster infects.in adolescents (12-18 yrs): 800 mg 4xdly x5 days.  sev.hepatomegaly with steatos.incl fatal.cases esp.women, sev.
   Contraindications: Safety in pregn.& lactat.not est., concom.  H.zoster & Varicella-zoster infects.in adults: 800 mg 5xdly at   ac. exacerbat. of hepatit.B aft.discont., lipodystrophy, paraesthes.,
   rifampicin.                  approx.4 hrly interv., omit night-time dos.x7 days.  perip. neuropathyl.onset neurologic. disord. in childr.expos. in utero,
   Side effects: Bld.dyscras., hypersens.reacts.incl. angioed./bron-  Sev.immunocomprom.pt: 800 mg 4xdly 6 hrly. In bone marrow   pancreatit., incr. AST/ ALT, rhabdomyolys., decr.bone miner.dens., os-
   chosp., hyponatraem., headache, insomn., N&V, diarrh., elev.liv.  recipients this would be preced.by up to 1 mnths ther.with IV ther.at   teopen., fract., allerg.react., hepatit., Freq unknown: Hypophospha-
                                     2
   enzym., fev., skin reacts. incl.Stev.John.syndr./erythema multiforme.  500 mg/m  3xdly. Treatm. durat.studied: 1-7 mnths post bone mar-  taem., dyspn., abdom. discomf., incr.amylase, ren.insuffic., ren.fail.,
   Special precautions: Absorpt.signific.incr.with food esp.high-fat,   row transplant & 12 mnths in adv.HIV dis.  Fanconi syndr., proxim.tubulopathy, proteinur., incr. creatin., ac.tubul.
   elderly, eval.caref.for caus.of any pulm. dis.other than PCP, not expect.  H.simplex treatm.& prophylax in immunocomprom. childr:   necros., nephrogen.diabet. insipid., polyur., intest.nephrit., myopathy,
   to be eff.treatm.for concurr.bact./vir./fung./mycobact. dis., sev.hepat.  2 yrs & old: Adult dos. Und. 2 yrs: ½ adult dos. Oral admin.to pts.   osteomalac., hypersens., immune reconstit.syndr
   impairm., concom.other meds., limit. data in pts.fail.other PCP ther./  und. 2 yrs. not fully stud. Varicella: 20 mg/kg bm not exceed 800 mg   Warnings and special precautions: Safety & effic. not est.in HBV
   sev.PCP episod./as PCP prophylax., immunosuppress. paed. pts., GI   4xdly.init.within 24 hrs.of sympts. x5 days. For sev.immunocomprom.  & HIV co-infects., monit. hepat.funct.for sev.mnths.in pts.co-infect.
   disords.may furth.reduc.absorpt.  childr. over 2 yrs.limit. data suggests use of adult dos.  with HIV & HBV who discont.ther.& appropr.init.of anti-hepatit. B
   Drug interactions: Reduc.lev.with rifampicin, decr.indinavir C min,   Contraindications: Safety in pregn.not est., lactat.  ther. poss.necess., eval.for signs of fat redistrib., CV risk assessm.in
   decr.ser.conc. with ritonavir.  Side effects: Skin rash, GI disturbs., revers. neurolog. reacts.par-  pts.with evid.of lipodystrophy, pts.to seek med.advice if exper.joint
                                tic.in ren.impairm/other predispos. fact., accelerat.diffuse hair loss,   pain/aches/stiffn./movem.diffic.as osteonecros. poss., opportun-
                                haematolog. changes           ist. infects.& other HIV complicat. may still devel., ARV ther.will not
   18.12   Anti-viral agents    Special precautions: In pts.follow.bone-marr. transplant.oral acy-  prev.transmiss. through sex.cont.& bld.transfus.& appropr.precaut. to
                                clovir must be preceded by 1 mnths acyclovir IV treatm., elderly, ren.
                                                              contin., discont.in pts.develop.clinic./lab.find. suggest. lact.acidos./
   ACRIPTEGA (MDR Listing)      impairm., concom.nephrotox.meds.incr.risk of ren.impairm.  hepatotox., pts.with known risk for liv.dis, pts.with hepatomegaly/
                                Drug interactions: Probenecid incr.plasma half-life.
   ADCO-EMTEVIR (MDR Listing)                                 hepatit/ other risk facts.for liv.dis./hepat.steatos., pts.co-infect. with
                                                              hepatit. C & treat.with alpha interferon & ribavarin, eff.on clinic.
   ALUVIA (MDR Listing)         ACITAB DT, Cipla Medpro [P/S]
   TRIVENZ (MDR Listing)        Acyclovir                     progress.of HIV-1 not demonstrat., investig.childr.expos.in utero
                                                              to nucleoside & nucleotide analog.for poss. mitochondr. dysfunct.
   ABACAVIR & LAMIVUDINE CIPLA 600/300, Cipla Medpro [P/S]  Indications: Init.& recurr.H.simplex.infects.of skin & mucous mem-  in case of relev.S&S, discont. ther. until pancreatit.excl.in cases of
   Abacavir sulph. 600 mg, lamivudine 300 mg  br.& genit.H.simplex.in both immunocompet.& immunocomprom.pts.,   N&V/abdom. pain/ elev. biochem.mark., ren.funct.impairm., monit.
                                suppress. of recurr.genit.H.simplex in immunocompet. pts., prophylax.
   Indications: Treatm.of HIV infect.adults & adolesc. from 12 yrs.  liv.funct.in pts.with pre-exist.liv.dysfunct., cons. ther.interrupt./dis-
   (S4) TABS, 47/20.2.8/1105    of H.simplex. infects.in immunocomprom.pts., treatm.of H.zoster. in-  cont.if evid.of worsen. liv.dis., poss.incr.conc.of Acriptega&/other
                                fects.if lesions not old. than 72 hrs., treatm.of Varicella zoster within
   722096-001: 30, R537,06      24 hrs.of typic.chickenpox les.  ren. elimin. meds with meds.reduc.ren.funct./compete for act. tu-
   Dosage: Pts.to be stabilis.on indiv.meds.bef. being switch.. As a fix.  (S4) DISPERS.TABS, 38/20.2.8/0129, 0128  bul.secret, monit.ren.funct.bef.init.ther & periodic.thereaft., avoid
   dos.tab.do not admin.to pts.weigh.less than 40 kg. Adults & ado-  704778-001: 200 mg, 25, R78,67  combin.with concurr./ recent nephrotox.meds., avoid in antiretrov.
   lesc.over 12 yrs: 1 tab.once dly.  704779-001: 400 mg, 60, R323,98  exper. pts. with HIV-1 harbour.K65R mutat., bone monit.in pts. with
   Contraindications: Mod.to sev.hepat.impairm., mod.to sev.ren.  Dosage:   patholog.bone fract.hist./osteopen.risk, incr. risk for sev.hepat.ad-
   impairm., safety in pregn.not est., lactat., childr.und.12 yrs., concom.  verse effs. in chron. hepatit.B or C co-infect., ref.to PI of concom.
   zalcitabine not recomm.      Init.& recurr.skin & mucous membr.H. simplex. infects:   hepat.B or C meds., immune reconstitut.inflam. syndr., limit.data in
                                Adults: 200 mg 5x/day (omit night time dos.) x5 days. In sev.infects.
   Side effects: Hepatotox.incl.lact.acidos./sev. hepatomegaly with   elderly &gt; 65 yrs., discont.ther. immed.if any hypersens.react.susp./
   steatos.& fatalit., hypersens. reacts.somet.fatal present.with fev.&/  extend. durat. of treatm. Sev. immunocompromis.pts./ pts.with   occurs.& init. appropr.ther., lact intol., avoid in wom.plan.pregn.,
                                imp.gut absorpt: Incr.dos.to 400 mg 5x/day or alternat.IV ther. Im-
   rash as part of syndr., anaphylax., anaem., neutropen., anorex., hy-  munocomprom. childr.2 yrs.& old: Adult dos. Below 2 yrs: ½   teratogenic.report., pregn.test in women of childbear.potent.bef.
   perlactataem., body fat redistribut., hypertriglyceridaem., hypercho-  adult dos.but data limit.  init./periodic.dur.treatm. & when pregn.suspect., lamivudine excret.
   lesterolaem., insul. resist., hyperglycaem., hyperlipidaem., insomn.,   Suppress.of recurr.H.simplex infects.in immunocompetent:   in breast milk, monit.with concom.co-trimoxazole, concom. ETR not
   abnorm. behav., headache, convuls., hyperton., pancreatit., N&V,   Adults: 200 mg 4xdly, OR 400 mg 2xdly. Dos.of 200 mg 3-2x/day   recomm.unless receiv.concom.ATV + RTV/ LPV + RTV or DRV + RTV,
   diarrh., rash, erythem. multiforme, Stev.John.syndr., tox.epiderm.   may prove effect. Interrupt period.to re-assess.condit.  admin.2 hrs.bef./6 hrs. aft. polyval.cation-cont.antacids, admin.2 hrs.
   necrolys., myalg., myosit., rhabdomyolys., fev., lethargy, fatig.,   H.simplex prophylax in immunocomprom.pts Adults:   bef./ 6 hrs. aft.Ca/Fe supplem.
   elev.LFT, ENT infects., lymphadenopathy, thrombocytopen., pure   200 mg 4xdly.  Interactions: lamivudine poss.inhib. intracellul. phosphorylat. of zal-
   red cell aplas., decr.appetit., depress./sleep disords., dizzin., par-  Sev.compromis.pts./pts.with imp.gut absorpt: Dos.may be   citabine, trimethoprim incr. lamivudine plasma lev., lamivudine incr.
   aesthes., periph.neuropathy, ear discharge, cough, nas.discharg./  doubl.to 400 mg.4xdly.or consid.IV ther. Durat.of ther.determin.by   expos.& peak. plasma lev. of zidovudine, conc.of tenofovir /concom.
   congest., wheez., abnorm. breath., sore throat, abdom.pain, sple-  med incr.with concom.drugs elimin.by glomerul.& act.tubul.secret.,
   nomegaly, stomatit., dyspeps., alopec., skin & subcut. tiss.pain   period at risk. Childr. 2 yrs.& old: Adults dos. Below 2 yrs: ½ adult   tenofov.ser.conc.incr. by agents decr.ren.funct., C max & AUC of didano-
                                dos.but data limit.
   & swell., urticar., prurit.,arthralg., musc. disords., musculoskelet.  Varicella-Zoster infects: Init.ASAP aft.rash appears. Adults:   sine incr., atazanavir incr.tenofovir C max/ AUC/ C min., lopinavir/ritonavir
   pain, osteonecros.           800 mg 5xdly omit night-time dos.x7 days. Sev.immunocompro-  incr.tenofovir AUC/ C min., indinavir incr.tenofovir C max, tenofovir incr.
   Warnings and special precautions: HLA-B*5701 allele screen.  mis.pts./pts. with imp.gut absorpt: consid.IV ther. Adolesc. 12-  C max of abacavir/indinavir, tenofovir incr. C max/ AUC/Cmin of ataza-
   advis.bef.ther.init.as assoc. with incr.hypersens.risk, discont.ther.in   18 yrs: 800 mg 4xdly x5 days. Immunocomprom.childr: 20 mg/kg   navir, poss.incr.metformin/ dofetilide/ pilsicainide plasma conc.with
   pts. develop. hypersens.& do not re-challenge as more sev. sympt.incl.  (not exceed. 800 mg) 4xdly.x5 days. In sev.immunocomprom. childr.   dolutegravir., poss.decr.dolutegravir conc.with oxcarbazepine/ pheny-
   life-threat.hypotens./death poss. return, pts.to be aware of dangers   over 2 yrs.of age adult dos.may be giv.but data limit.  toin/phenobarb./ carbamazepine/ St John’s Wort though no studies,
   of hypersens., use facil.where medic.assist.avail.if ther.restart, incr.   Sev.immunocomprom.pts: 800 mg 4xdly.at 6 hr interv. Bone marr.  reduc. dolutegravir plasma conc.with etravirine/ efavirenz/ nevirap-
   risk of sev./potent.fatal hepat.adverse react. in co-infect.hepatit.B/C   recipients to receiv.IV ther.3xdly. x1 mnth.prior to oral ther. Ther.du-  ine/rifampicin, incr.dolutegravir plasma conc.with atazanavir, decr.
   pts., per.monit.recomm.if discont. in pts.co-infect.with hepat.B virus   rat:6-12 mnths. in adv.HIV dis.  dolutegravir conc. with tipranavir + ritonavir/fosamprenavir + ritonavir.
   as lamivudine withdr.poss.result in rebound hepatit., obese women/  Contraindications: Valaciclovir hypersens., safety in pregn.&   See also MDR page 530.
   prolong.nucleosid.expos./with MI/ hepatomegaly/ hepatit./any liv.dis.  lactat.not est.
   risk fact./ hepat. steatos., monit.for lact.acidos.& discont. ther. in case   Side effects: Bld.dyscras., headache, fatig., revers. neurolog.reacts.,   ACYCLOVIR BIOTECH, Biotech [P/S]
   of rais.lactat.lev, eval.for physic.signs of fat redistribut., meas.fast.ser.  GI disturbs., ac.ren.fail., hepatit., jaund., diffuse hair loss, hypersens.   Acyclovir
   lipids/bld.gluc., opportunist. infects.& other HIV complicat.may still   reacts. incl.anaphylax.  Indications: Init.& recurr.H.simplex.infects.of skin/mucous membr.&
   devel., advis.pt.that antiretrovir.ther.will not prev. transmiss. through   Special precautions: Sev.ren.impairm., weigh risk vs benefit in   genit.H.simplex, recurr. H.simplex. infects.suppress.in pts.with incom-
   sex.cont./bld.contam. & appropr. precaut.to contin., not recomm.in   pregn.& lactat., adeq.hydrat.with high dos., elderly.  pet. immune syst., shingles if les.not old.than 72 hrs., treatm. of vari-
   creat. clear. less than 50 ml/min., discont.ther.until pancreatit. excl.if   Drug interactions: Probenecid decr.ren.excret.  cella-zoster/chicken pox virus within 24 hrs.of typic. chickenpox rash,
   poss.sympts.develop, MI risk fact., pt.monit.with concom.co-trimox-  reduc.herpes infect. risk in HIV pos.pts.who are sev. immunocomprom.
   azole, concom. methadone retitrat.poss.reqd., reproduct. toxic. in ani-  ACITOP, (iNova) Cipla Medpro [P/S]  poss.with concom.zidovudine in advanc.HIV dis.
   mals, excret.in breast milk, no studies in pts.&gt;65 yrs.,   Acyclovir  (S4) TABS, 31/20.2.8/0430
   Drug interactions: Lamivudine poss.inhib. zalcitabine intracell.   Indications: H.simplex infects.of lips in init.& recurr.situat.  719670-002: 200 mg, 25, R59,41
   phosphorylat., abacavir AUC incr. by ethanol, methadone reduc.  (S1) CREAM. 32/20.2.8/0719.  719670-001: 200 mg, 100, R237,62
   abacavir AUC &1 hr delay in t max., trimethoprim incr.lamivudine expos.  873551-001: 50 mg/g, 2 g, R26,92  Dosage: Init.& recurr.skin & mucous membr. H.simplex.in-
                                                              fects: 200 mg 5x/dly.at 4 hrly. interv. x5 days. In sev.infect.treatm.
   ACICLOVIR SANDOZ 200 & 400, Sandoz [P/S]  Dosage: Adults & childr: Init.as soon as poss. esp. recurr.episod.   per.may be extend.in immunocompromis.pts.incr.dos.to 400 mg. First
                                Cover.all.lesions adeq.5-6x/ day at 4 hrly.interv.x5-10 days. Do not
   Aciclovir                    exceed recomm. dos.           dos.to be admin.as early as poss. aft.infect.start.
   Indications: Init.& recurr.H.simplex.infects.of skin/mucous mem-  Side effects: Trans.burn./sting., erythem., mild dryn. & skin flak.  Suppress.of recurr.genit.H.simplex infects. in immunocom-
   br.& genit.H.simplex, init.& recurr. genit.H. simplex., prophylax.of   Special precautions: Safety in pregn.not est., cutan.use only, poss.  promis.pts: 200 mg 4xdly, 6 hrly. /400 mg 12 hrly. Interrupt at
   H.simplex. infects. in immunocompromis.pts., treatm.of H. zoster.   varicella zoster resist., not recomm.for muc.membr.applic., prev.auto   6-12 mnthly.interv.to observe dis.hist.
   infects.if lesions not older than 72 hrs., treatm. of Varicella-Zoster   innoculat. by apply.with fing.cot/rubb.glove, avoid cont.with eyes.  H.simplex prophylax. in immunocompromis. pts: 200 mg
   within 24 hrs.of typical chickenpox rash, reduct.of mortal.& risk of   4xdly 6 hrly. Dos.may be doubl.to 400 mg in sev.compromis.pts./pts.
   develop. H.virus infect.in cert.sev. immunocomprom. pts./follow.  ACRIPTEGA, Mylan &  with imp.gut absorpt.
   bone marr. transplantat.     Lamivudine 300 mg, tenofovir disoproxil fumarate 300 mg, dolute-  Varicella zoster infects.in adolescents (12-18 yrs): 800 mg
   (S4) TABS, 32/20.2.8/0378, 0379  gravir sod. 50 mg         4xdly x5 days.
   884972-005: 200 mg, 25, R66,64  Indications: Treatm.of HIV infect.adults ≥ 18 yrs.  H.zoster & Varicella-zoster infects.in adults: 800 mg 5xdly at
   884979-005: 400 mg, 70, R254,53  (S4) TABS, 52/20.2.8/0199  4 hrly interv. x7 days.
   Dosage: Init.& recurr.skin & mucous membr. H.simplex.in-  3000426-001: 30, R494,99  Sev.immunocompromis.pts: 800 mg 4xdly 6 hrly.
   fects: Adults: 200 mg 5x/dly.at approx. 4 hrly.interv., omit night-  Dosage: Consult.prod.info.of each therapeut. compon. of regim.bef.  H.simplex treatm.& prophylax in immunocomprom. childr:
   time dos.x5 days. Treatm. per.may be extend.if neccess. In sev. im-  init.treatm., init.ther.by physic. exper.in HIV infect.managem. Adults:   2 yrs & old: Adult dos. Oral admin.to pts.und.2 yrs. not fully stud.
   munocompromis.pts./pts.with imp.gut absorpt. dos. may be doubl.  1 tab. once dly. Rifampicin decr.bld.lev.of dolutegravir & supplement.  Varicella zoster treatm.in childr.bel.2 yrs: 20 mg/kg bm 4x dly.
   to 400 mg or alternat.IV ther.  dos.of dolutegravir poss.requir.  for 5 days not exceed 800 mg dly. Start ther.as soon as chicken-
   Suppress.of recurr.genit.H.simplex infects.in immunocompe-  Contraindications: Ren.funct.impairm., pregn.& lactat., wom.of   pox rash appears.
   tent adults: 200 mg 4xdly, 6 hrly. /400 mg 2xdly 12 hrly. Titrat.down   child-bear.age not using high. effect. contracept., concom.adefovir   Contraindications: Safety in pregn.& lactat.not est.</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page296.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page292.html">292</a>&nbsp;&nbsp;&nbsp;<a href="page293.html">293</a>&nbsp;&nbsp;&nbsp;<a href="page294.html">294</a>&nbsp;&nbsp;&nbsp;<a href="page295.html">295</a>&nbsp;&nbsp;&nbsp;<a href="page296.html">296</a>&nbsp;&nbsp;&nbsp;<a href="page297.html">297</a>&nbsp;&nbsp;&nbsp;<a href="page298.html">298</a>&nbsp;&nbsp;&nbsp;<a href="page299.html">299</a>&nbsp;&nbsp;&nbsp;<a href="page300.html">300</a>&nbsp;&nbsp;&nbsp;<a href="page301.html">301</a>&nbsp;&nbsp;&nbsp;<a href="page302.html">302</a>
             </td>
             <td width="35%"><a href="page298.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page298.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
